Last updated: October 5, 2026
Brethine is the former U.S. brand for terbutaline sulfate, a short-acting beta-2 adrenergic agonist used primarily for bronchospasm. Its commercial value has largely migrated from the branded product to low-cost generic terbutaline, while inhaled albuterol and newer long-acting bronchodilators have taken share in asthma and obstructive airway disease. Brethine has no identifiable current brand franchise with publicly reported standalone revenue, and its economic importance is now limited to legacy brand recognition, generic substitution, hospital use, and supply availability.
What is Brethine and who marketed the drug?
Brethine is terbutaline sulfate, a sympathomimetic bronchodilator. Historical U.S. presentations included oral tablets and injectable products. Terbutaline is also marketed under generic labels and has been used in hospital settings for acute bronchospasm and, outside approved indications, for short-term suppression of preterm labor.
| Attribute |
Brethine |
| Active ingredient |
Terbutaline sulfate |
| Drug class |
Short-acting beta-2 adrenergic agonist |
| Main historical use |
Bronchospasm and asthma |
| Dosage forms |
Tablets and injection |
| U.S. brand status |
Legacy/discontinued brand market |
| Current commercial market |
Generic terbutaline products |
| Biologic status |
Small-molecule drug; biosimilar pathway does not apply |
| Primary substitutes |
Albuterol, levalbuterol, inhaled corticosteroids, LABA therapies |
| Current revenue disclosure |
No standalone public Brethine revenue reported |
Historical Brethine sales were associated with Ciba-Geigy and later Novartis-related commercial operations. The brand’s commercial life predates the current structure of the U.S. generic pharmaceutical market. Generic terbutaline manufacturers now supply the active market.
What is the FDA regulatory status of Brethine?
The FDA regulatory position is best understood by separating the historical brand from currently marketed terbutaline products.
Brethine is not a significant current branded FDA franchise. The relevant U.S. market consists principally of generic terbutaline sulfate products, especially injectable formulations. FDA labeling identifies terbutaline injection for the prevention and treatment of bronchospasm in patients with reversible obstructive airway disease. Oral terbutaline has a substantially narrower commercial role.
The FDA has taken a restrictive position on terbutaline for obstetric use. In 2011, the agency warned against using oral terbutaline for prevention or treatment of preterm labor and against prolonged use of injectable terbutaline for that purpose because of maternal cardiovascular risks. The agency stated that terbutaline should not be used for outpatient or prolonged treatment of preterm labor. These restrictions reduced a historical off-label demand channel. (U.S. Food and Drug Administration, 2011)
FDA milestones affecting commercial demand
| Date |
Regulatory event |
Commercial effect |
| Historical period |
Brethine marketed for bronchospasm |
Established the brand and clinical awareness |
| Genericization period |
Terbutaline products entered the market |
Reduced branded pricing power |
| 2011 |
FDA warning on obstetric use |
Restricted a material off-label demand channel |
| Current period |
Generic terbutaline remains available in selected presentations |
Market is primarily price-driven |
What is the Orange Book status of Brethine?
Brethine does not represent a meaningful current Orange Book exclusivity position. The market has long passed the period in which brand patents or regulatory exclusivity could protect premium pricing.
The FDA Orange Book remains the principal source for identifying listed patents, exclusivity, and therapeutic-equivalence information for approved prescription products. A current review of the relevant terbutaline entries is necessary to distinguish historical Brethine approvals from actively marketed generic products. The commercial conclusion is clear: generic terbutaline competes without dependence on a live Brethine brand monopoly. (U.S. Food and Drug Administration, 2024a)
Are there active Brethine patents?
No commercially meaningful active patent estate is associated with the legacy Brethine brand. The underlying molecule, terbutaline, is an old small molecule. Any historical composition-of-matter protection has expired, and generic competition has existed for many years.
Potentially relevant intellectual-property categories include:
- Terbutaline sulfate composition and salt forms.
- Tablet formulations.
- Injectable formulations.
- Manufacturing and purification processes.
- Packaging, stability, and dosing systems.
These categories do not create a material barrier to ordinary generic terbutaline competition. Formulation or process patents, if asserted for a particular product, would not recreate broad exclusivity for the legacy Brethine brand.
When did Brethine lose exclusivity?
Brethine lost practical market exclusivity after generic terbutaline products became available. The precise commercial transition date depends on the dosage form, dosage strength, and historical approval sequence. The relevant point for investors is that exclusivity ended decades ago rather than approaching expiration today.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Composition-of-matter patent |
Expired |
| Brand-level market exclusivity |
Expired |
| Formulation protection |
No known broad commercial barrier |
| Pediatric exclusivity |
Not material to current market |
| Orphan exclusivity |
Not applicable |
| Biosimilar reference-product protection |
Not applicable |
Brethine therefore has no credible “patent cliff” remaining. Its decline occurred through gradual generic substitution rather than a future single-date loss of protection.
How many patents cover terbutaline and Brethine?
No active patent portfolio appears to provide broad commercial protection for Brethine or the terbutaline active ingredient. Historical patents may remain relevant to the product’s development history, but they do not support current brand exclusivity.
The practical patent-risk assessment is:
| Patent issue |
Risk to generic terbutaline |
| Active molecule patent |
Low |
| Basic salt patent |
Low |
| Standard tablet formulation |
Low |
| Standard injectable formulation |
Low |
| Manufacturing know-how |
Moderate for quality and supply execution, not market exclusivity |
| Device or delivery-system patent |
Low for conventional products |
| Method-of-use patent |
Low for core bronchospasm use |
| Litigation-driven delay |
Low based on the legacy brand’s market position |
Manufacturing know-how can affect product quality, sterility, yield, and regulatory approval. It does not normally prevent multiple manufacturers from competing in an old, established molecule.
What formulations are protected by Brethine patents?
There is no evidence that currently marketed terbutaline tablets or injections rely on a commercially important active Brethine formulation patent. The conventional formulations are technically mature.
Oral tablets
Terbutaline tablets are simple immediate-release dosage forms. Competition is generally determined by:
- FDA approval and therapeutic equivalence.
- Active pharmaceutical ingredient sourcing.
- Tablet manufacturing cost.
- Wholesaler and pharmacy contracting.
- Product availability.
Injectable terbutaline
Injectable terbutaline has more demanding manufacturing requirements because of sterility, container closure, stability, and quality-control obligations. Those requirements can produce supply barriers, but they are regulatory and operational barriers rather than patent exclusivity.
Hospitals may maintain more than one supplier because injectable shortages can affect emergency and obstetric care. Supplier reliability can therefore matter more than brand identity.
Which companies compete with Brethine and terbutaline?
The competitive market has two layers: direct generic terbutaline suppliers and therapeutic substitutes.
Direct generic competition
Generic terbutaline products may be supplied by manufacturers such as Hikma Pharmaceuticals, Rising Pharmaceuticals, Amneal Pharmaceuticals, and other FDA-approved or authorized suppliers depending on product presentation and market period. Manufacturer participation can change as firms discontinue products, transfer approvals, or enter during shortages.
The relevant competition is not limited to one branded successor. It is a fragmented generic market in which purchasing organizations evaluate price, supply continuity, manufacturing quality, and shortage history.
Therapeutic competition
| Competitor |
Category |
Competitive impact |
| Albuterol |
Short-acting beta-2 agonist |
Main substitute in acute bronchodilation |
| Levalbuterol |
Short-acting beta-2 agonist |
Alternative for selected patients |
| Inhaled corticosteroids |
Anti-inflammatory controller |
Reduces reliance on rescue bronchodilators |
| ICS/LABA products |
Maintenance therapy |
Competes in chronic asthma management |
| Other LABAs |
Long-acting bronchodilators |
More relevant in chronic obstructive disease |
| Nebulized bronchodilators |
Delivery-based substitutes |
Compete in hospital and home-care settings |
Albuterol has a stronger modern market position in rescue therapy. Terbutaline remains clinically relevant where injectable or oral beta-2 agonist treatment is selected, but it is not the default branded rescue product in the United States.
What generic entry risks exist for Brethine?
Generic entry risk is no longer a future threat to Brethine. It is the reason the branded product has little current economic value.
Generic competition affects terbutaline through five mechanisms:
- Lower acquisition prices.
- Substitution at the pharmacy or hospital level.
- Multiple approved suppliers.
- Limited patient loyalty to a legacy brand.
- Therapeutic substitution to albuterol and other bronchodilators.
For any remaining Brethine-branded inventory, the principal risks are product discontinuation, channel contraction, formulary exclusion, and replacement by generic or therapeutically preferred products.
Are there Paragraph IV challenges involving Brethine?
Paragraph IV litigation is not a material current issue for Brethine. Paragraph IV certifications challenge patents listed for a reference drug in an abbreviated new drug application. Because the core Brethine exclusivity period has expired and no significant current brand patent barrier is evident, a new Paragraph IV-driven market event is unlikely.
Historical generic entry may have involved ordinary ANDA certifications or patent-status determinations. Those events do not create current launch uncertainty for a legacy product. The commercially relevant risk is supply interruption, not a patent challenge to a protected brand.
What patent litigation affects Brethine?
No significant ongoing patent litigation is associated with the legacy Brethine franchise. The product’s legal profile is materially different from newer branded medicines that face active patent challenges, settlement negotiations, or authorized-generic launches.
Litigation and settlement assessment
| Issue |
Assessment |
| Active brand patent litigation |
Not material |
| Paragraph IV litigation |
Not material to current market |
| Generic settlement agreement |
No commercially important current settlement identified |
| Antitrust exposure |
Low based on the legacy product profile |
| Label litigation |
Possible product-liability exposure in principle, but not a market-exclusivity issue |
| Regulatory enforcement |
FDA warnings on obstetric use remain commercially relevant |
What licensing deals involve Brethine?
Brethine has no publicly disclosed current licensing structure that supports a material branded revenue stream. Historical rights may have moved through corporate transactions involving Ciba-Geigy, Novartis, and successor commercial entities, but those historical arrangements do not appear to support present-day market exclusivity.
Generic terbutaline supply agreements are more likely to involve ordinary manufacturing, distribution, contract supply, or pharmacy purchasing arrangements. These agreements generally do not create durable intellectual-property value.
What is the financial trajectory of Brethine?
Brethine’s financial trajectory follows the standard pattern for an old small-molecule brand:
- Initial branded growth based on clinical adoption.
- Expansion through multiple dosage forms and indications.
- Generic entry and price erosion.
- Loss of formulary and pharmacy shelf space.
- Decline of brand revenue.
- Residual value concentrated in generic supply and hospital demand.
No public company currently reports Brethine as a distinct revenue line. Public financial statements typically aggregate old products within broader portfolios, making brand-specific revenue unavailable. The economic value of terbutaline is therefore better assessed through market structure than through a reported Brethine sales forecast.
Financial drivers
| Driver |
Directional effect |
| Generic substitution |
Strongly negative for brand revenue |
| Albuterol competition |
Negative |
| Hospital injectable demand |
Positive for selected generic suppliers |
| Obstetric-use restrictions |
Negative |
| Drug shortages |
Can temporarily increase supplier pricing and volume |
| Low production cost |
Negative for long-term price levels |
| Multiple suppliers |
Negative for pricing power |
| Regulatory quality requirements |
Positive for reliable manufacturers |
| Brand recognition |
Limited ability to support premium pricing |
The residual opportunity is concentrated in operational execution. A manufacturer with an approved injectable product, dependable sterile capacity, and reliable distribution may generate stable generic revenue. That opportunity is distinct from a Brethine brand investment thesis.
How does Brethine compare with albuterol?
Albuterol has the stronger current commercial position in acute inhaled bronchodilation. It is widely prescribed, available in inhalers and nebulized forms, and integrated into modern asthma treatment protocols. Terbutaline is more specialized in the United States, with injectable use providing a differentiated hospital role.
| Factor |
Brethine/terbutaline |
Albuterol |
| Brand status |
Legacy |
Active generic and branded markets |
| Primary delivery |
Tablets and injection |
Inhalers and nebulizers |
| Rescue use |
Selective |
Mainstream |
| Patent position |
Expired |
Mostly generic, with device/formulation variation |
| Hospital relevance |
Injectable use |
Nebulized and inhaled use |
| Pricing power |
Minimal |
Minimal for core generic products |
| Commercial growth |
Limited |
Larger underlying market |
| Regulatory risk |
Obstetric-use restrictions |
Device and inhaler-quality requirements |
What geographic markets remain relevant?
The United States is no longer a branded Brethine growth market. It is a generic terbutaline market with demand concentrated in hospitals, selected outpatient prescriptions, and supply-constrained settings.
International markets may retain terbutaline products under local brand names or generic labels. Regulatory status, approved indications, reimbursement, and obstetric practice differ by country. A global revenue estimate cannot be assigned to Brethine without separating the legacy brand from terbutaline products marketed under other names.
Geographic commercial value is therefore determined by:
- Local generic competition.
- National reimbursement rules.
- Hospital procurement.
- Availability of injectable products.
- Local restrictions on obstetric use.
- Registration status of oral and injectable presentations.
What manufacturing and intellectual-property barriers exist?
The molecule presents limited intellectual-property barriers. Manufacturing barriers are more relevant for injectable terbutaline.
Oral product barriers
Oral tablets are relatively straightforward to manufacture. The primary risks involve API qualification, content uniformity, stability, packaging, and regulatory compliance.
Injectable product barriers
Injectables require:
- Sterile manufacturing capacity.
- Validated aseptic processes.
- Container-closure integrity.
- Stability data.
- Batch-release testing.
- Reliable API and excipient supply.
- FDA compliance with current good manufacturing practices.
These requirements can limit the number of dependable suppliers. They can also create temporary pricing opportunities during shortages. They do not produce durable branded exclusivity.
What is the investment outlook for Brethine?
Brethine does not support a conventional branded-pharmaceutical investment thesis. The brand has no evident future patent catalyst, no meaningful exclusivity runway, and no disclosed standalone revenue base. The investable opportunity, if any, lies in generic terbutaline supply, especially injectable products, rather than in ownership of the legacy Brethine name.
A diligence model should focus on:
- Approved product presentations.
- Current supplier count.
- FDA shortage history.
- Sterile manufacturing capacity.
- Hospital contract exposure.
- Net selling price and gross margin.
- API sourcing concentration.
- Product discontinuation risk.
- Competition from albuterol and newer inhaled therapies.
Key Takeaways
- Brethine is the legacy brand for terbutaline sulfate.
- The branded franchise has no meaningful current exclusivity.
- Generic terbutaline is the relevant U.S. commercial market.
- No active patent estate appears to protect the core molecule or conventional formulations.
- Paragraph IV litigation and patent settlements are not current commercial drivers.
- FDA restrictions on obstetric use reduced a historical off-label demand channel.
- Albuterol is the principal therapeutic and commercial substitute.
- Injectable terbutaline retains niche hospital value because sterile supply can be constrained.
- No standalone public Brethine revenue is reported.
- The product’s future economics depend on generic manufacturing and supply reliability, not brand pricing power.
FAQs
Is Brethine still available in the United States?
The Brethine brand is not a significant current U.S. commercial product. Terbutaline sulfate remains available through generic products, particularly in selected injectable presentations.
Is terbutaline the same drug as Brethine?
Yes. Brethine was a brand name for terbutaline sulfate. Current products are generally sold under generic labeling or other local brand names.
Can terbutaline still be used for preterm labor?
FDA warnings restrict oral terbutaline for prevention or treatment of preterm labor and discourage prolonged or outpatient injectable use for that purpose because of serious maternal cardiovascular risks. (U.S. Food and Drug Administration, 2011)
Does terbutaline have biosimilar competition?
No. Terbutaline is a small-molecule drug, so it is regulated through generic-drug pathways rather than the FDA biosimilar pathway.
Is there a future patent cliff for Brethine?
No. Brethine’s principal patent and exclusivity periods expired long ago. Current commercial risk relates to generic pricing, supply continuity, and therapeutic substitution.
References
-
U.S. Food and Drug Administration. (2011). FDA drug safety communication: New warnings against use of terbutaline to treat preterm labor. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. National Library of Medicine. (2024). Terbutaline sulfate injection: Drug labeling. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. National Library of Medicine. (2024). Terbutaline sulfate tablet: Drug labeling. DailyMed. https://dailymed.nlm.nih.gov/
